Cystic Fibrosis
Conditions
Keywords
azithromycin, cystic fibrosis, pulmonary function
Brief summary
Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients. It was shown that this treatment taken every day or every week for 12 months, can improve the respiratory state of patients. From the second year of treatment, it would appear there is more profit to continue such treatment. The main objective is to study the association between continuous use of azithromycin and lung function measured by Forced expiratory volume in one second (FEV1), after two years of treatment.
Interventions
DRUGAzithromycin
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
7 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with Cystic Fibrosis (whatever the genetic form) * Age ≥ 8 years * FEV ≥ 30% the year of azithromycin (N0) * Continuous treatment with azithromycin for at least 2 years.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced expiratory volume in one second (FEV1). | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI) | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin |
| Number of IV antibiotics cures | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin |
| Pseudomonas aeruginosa colonization | yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin |
Countries
France
Outcome results
None listed